Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop #2

When: February 11, 2013 - February 12, 2013 (8:30 AM Eastern)
Where: Keck Center (Room 100) • 500 Fifth St. NW, Washington, DC 20001

Topics Biomedical and Health Research, Diseases, Health Care Workforce, Health Services, Coverage, and Access, Quality and Patient Safety
Activity: National Cancer Policy Forum
Board: Board on Health Care Services

This workshop was co-sponsored by the Institute of Medicine and the American Society of Clinical Oncology (ASCO).

This workshop examined ongoing activities in the implementation of the recommendations put forth in the IOM consensus report, A National Cancer Clinical Trials System for the 21st Century. This was the second part to a two-part workshop series. The first workshop was held in early 2011 and invited all stakeholders charged with making changes to the system to discuss what changes they planned to implement in response to the IOM recommendations. This follow-up workshop reconvened these key stakeholders to discuss progress made to date and to identify additional actions to take. Workshop sessions and discussions highlighted progress made by NCI and the Clinical Trials Network, funding needs and opportunities, strategies for prioritizing trial concepts, ongoing and future implementation challenges, opportunities for the development of effective partnerships to accelerate innovation, and current regulatory issues.

Monica M. Bertagnolli (chair), Alliance for Clinical Trials In Oncology and Dana-Farber Cancer Institute
Amy P. Abernethy, Duke University School of Medicine
Michael A. Caligiuri, Comprehensive Cancer Center at the Ohio State University
Renzo Canetta, Bristol-Myers Squibb Company
Michaele Chamblee Christian, retired
James H. Doroshow, NCI
Patrick Gavin, Patrick Gavin R.Ph. Consulting LLC
Gregory H. Reaman, FDA
George W. Sledge, Jr., Indiana University Simone Cancer Center
Ralph R. Weichselbaum, The University of Chicago Medical Center
Robin Zon, Northern Indiana Cancer Research Consortium CCOP

Jeffrey Abrams, CTEP and NCI Division of Cancer Treatment and Diagnosis
Peter Adamson, Children's Oncology Group
Margaret Anderson, FasterCures
Edward Benz, Dana-Farber Cancer Institute
Charles Blanke, SWOG and OHSU Knight Cancer Institute
Renzo Canetta, Bristol-Myers Squibb
Renaud Capdeville, Novartis Oncology
Robert Comis, ECOG-ACRIN Cancer Research Group
Barbara Conley, NCI
Walter Curran, NRG Oncology Group and Emory Winship Cancer Institute
Robert Diasio, Mayo Clinic Cancer Center
Joseph DiMasi, Tufts Center for the Study of Drug Development
Lori Dodd, NCI Biostatistics Research Branch
James H. Doroshow, NCI Division of Cancer Treatment and Diagnosis
Hans-Georg Eichler, European Medicines Agency, NEWDIGS Initiative, MIT Center for Biomedical Innovation
Levi Garraway, Dana-Farber Cancer Institute
Patrick Gavin, Patrick Gavin R.Ph. Consulting LLC
Stephen Grubbs, Helen F. Graham Cancer Center and Christiana Care CCOP
Sandra Horning, Genentech
Robert Iannone, Merck Research Laboratories
Richard Kaplan, UK National Cancer Research Network and Medical Research Council
Worta McCaskill-Stevens, NCI Division of Cancer Treatment and Diagnosis
Lisa McShane, NCI Division of Cancer Treatment and Diagnosis
John Mendelsohn, MD Anderson Cancer Center
Vincent Miller, Foundation Medicine
Richard Pazdur, FDA Office of Hematology and Oncology Products
Francesco Pignatti, European Medicines Agency
Nancy Roach, Fight Colorectal Cancer
Debasish Roychowdhury, Sanofi Oncology
Marc Sabatine, Thrombolysis in Myocardial Infarction (TIMI) Study Group
Richard Schilsky, American Society of Clinical Oncology
Rachel Sherman, FDA Office of Medical Policy
George W. Sledge, Jr., Stanford University School of Medicine
David Solit, Memorial Sloan-Kettering Cancer Center
Robin Zon, Michiana Hematology Oncology, PC and Northern Indiana Cancer Research Consortium CCOP

Upcoming Meetings for this Activity

Previous Meetings for this Activity

Also of Interest